Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab
D. Ngo(Hunter Medical Research Institute), Aaron L. Sverdlov(Hunter New England Local Health District), Janette L. Vardy(The University of Sydney), James Lynam, Tony Bonaventura(St Vincent’s Private Hospital Sydney), Ina Nordman(Calvary Mater Newcastle Hospital), Sophie Horder(University of Newcastle Australia), Hiren Mandaliya(Lake Macquarie Private Hospital), Trent Williams(Hunter New England Local Health District), Leonard Kritharides(The University of Sydney)
Cited by 30
Related Papers
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Visualizing lipid structure and raft domains in living cells with two-photon microscopy
|Proceedings of the National Academy of Sciences|2003|520